High‐grade B‐cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib

Tyrosine kinase inhibitor (TKI) can help to increase the survival time in chronic myeloid leukemia (CML) patients; however, the risk of secondary malignancies due to TKIs is a growing concern. Only few reports showed clinical course of patients who developed lymphoma during TKI therapies. Herein, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Takakuwa, Teruhito, Sakai, Ryota, Koh, Shiro, Okamura, Hiroshi, Nanno, Satoru, Nakashima, Yasuhiro, Nakane, Takahiko, Koh, Hideo, Hino, Masayuki, Nakamae, Hirohisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981704/
https://www.ncbi.nlm.nih.gov/pubmed/33768841
http://dx.doi.org/10.1002/ccr3.3770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981704/
https://www.ncbi.nlm.nih.gov/pubmed/33768841
http://dx.doi.org/10.1002/ccr3.3770

Ejemplares similares